ArticleCureus2025
Serious Bacterial Infection Risk in Febrile Infants Aged ≤90 Days With COVID-19.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background This retrospective cohort study compared the risk of serious bacterial infection (SBI) in febrile infants aged ≤90 days with and without COVID-19. While some studies have suggested that COVID-19-positive febrile infants may have a lower risk of SBI, this remains unclear, particularly in Japan. We investigated the incidence of SBI and clinical characteristics in COVID-19-positive versus COVID-19-negative febrile infants. Methods Febrile infants aged ≤90 days who visited the emergency department of the children's hospital in Japan between April 2021 and November 2022 were enrolled. The subjects were divided into a COVID-19 group, defined as subjects with positive polymerase chain reaction (PCR) findings for SARS-CoV-2 or those with close contact with a SARS-CoV-2 PCR-positive family member. SBI was defined as urinary tract infection (UTI), bacterial pneumonia, bacteremia, or bacterial meningitis. Results In total, 396 patients were included; of these, 125 patients were in the COVID-19 group. SBI was diagnosed in 7/125 patients (5.6%) of this group vs. 45/271 patients (16.6%) of the non-COVID-19 group (p<0.05). All cases of SBI diagnosed in the former were of UTI. No notable differences in respiratory or gastrointestinal symptoms were observed between patients with and without SBI. Conclusion The present study demonstrated that the SBI rate was significantly lower in the COVID-19 group than in the non-COVID-19 group. However, the complication rate of SBI, especially UTI, was not negligible, suggesting that at least urinalysis should be performed for target patients. Our study provided more evidence to support the published data pertaining to the risk of SBI in febrile infants with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.